Immune Regulation News Volume 5.27 | Jul 19 2013

    0
    73
    Immune Regulation News 5.27 July 19, 2013

    Pulmonary Cell News

         In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
    Cell Therapy News on Facebook Immune Regulation News on Twitter

     
    TOP STORY
    A Secret to Making Macrophages
    Biologists have worked out the details of a mechanism that leads undifferentiated blood stem cells to become macrophages- immune cells that attack bacteria and other foreign pathogens. The process involves an unexpected cycle in which cell division slows, leading to an increased accumulation of a particular regulatory protein that in turn slows cell division further. [Press release from the California Institute of Technology discussing online prepublication in Science] Press Release | Abstract | Video
    A New System for High-Throughput Cell Isolation Directly from Whole Blood

     
    PUBLICATIONS (Ranked by impact factor of the journal)
    Antiapoptotic Mcl-1 Is Critical for the Survival and Niche-Filling Capacity of Foxp3+ Regulatory T Cells
    The authors report that peripheral Foxp3+ regulatory T cells markedly alter their proliferative and apoptotic rates to rapidly restore numerical deficit through an interleukin 2-dependent and costimulation-dependent process. [Nat Immunol] Abstract | Press Release

    Intravenous Immunoglobulin Expands Regulatory T Cells via Induction of Cyclooxygenase-2-Dependent Prostaglandin E2 in Human Dendritic Cells
    As CD4+CD25+FoxP3+ regulatory T cells (Tregs) expansion in the periphery requires signaling by antigen presenting cells such as dendritic cells (DCs) and that intravenous immunoglobulin (IVIg) has been demonstrated to modulate DC functions, investigators hypothesized that IVIg induces distinct signaling events in DCs that subsequently mediate Treg expansion. They demonstrated that IVIg expands Tregs via induction of cyclooxygenase-2-dependent prostaglandin E2 in human DC. [Blood] Abstract

    Transient B Cell Depletion Combined with Apoptotic Donor Splenocytes Induces Xeno-Specific T and B Cell Tolerance to Islet Xenografts
    Peritransplant infusion of apoptotic donor splenocytes cross-linked with ethylene carbodiimide (ECDI-SPs) has been demonstrated to effectively induce allogeneic donor-specific tolerance. Researchers aimed to determine the effectiveness and additional requirements for tolerance induction for xenogeneic islet transplantation using donor ECDI-SPs. In a rat-to-mouse xenogeneic islet transplant model, they showed that rat ECDI-SPs alone significantly prolonged islet xenograft survival, but failed to induce tolerance. [Diabetes]
    Abstract
    | Press Release

    Modulation of CD8+ T Cell Responses to AAV Vectors with IgG-Derived MHC Class II Epitopes
    Using MHC class II epitopes initially identified within human IgG, named Tregitopes, researchers showed that it is possible to modulate CD8+ T cell responses to several viral antigens in vitro. They showed that incubation of peripheral blood mononuclear cells with these epitopes triggers proliferation of CD4+CD25+FoxP3+ T cells that suppress killing of target cells loaded with MHC class I antigens in an antigen-specific fashion, through a mechanism that seems to require cell-to-cell contact. [Mol Ther] Abstract

    Membrane-Type 6 Matrix Metalloproteinase Regulates the Activation-Induced Downmodulation of CD16 in Human Primary NK Cells
    Scientists identified membrane-type 6 (MT6) matrix metalloproteinase (MMP) (also known as MMP25) as a proteinase responsible for CD16 downmodulation. IL-2-induced upregulation of MT6/MMP25 cell-surface expression correlates with CD16 downmodulation. [J Immunol] Abstract

    Tumor-Infiltrating Regulatory T Cells Inhibit Endogenous Cytotoxic T Cell Responses to Lung Adenocarcinoma
    The authors examined immune complexity of human nonsmall cell lung cancers (NSCLC) as well as NSCLC developing in CC10-TAg transgenic mice, and revealed that CD4+ T lymphocytes represent the dominant population of CD45+ immune cells, and, relative to normal lung tissue, CD4+Foxp3+ regulatory T cells were significantly increased as a proportion of total CD4+ cells. [J Immunol] Abstract

    Human Cytomegalovirus Viral IL-10 Polarizes Monocytes Towards a Deactivated M2c Phenotype to Repress Host Immune Responses
    Investigators identified a novel role for viral interluekin (IL)-10 in driving M2c polarization which may limit virus clearance by restricting pro-inflammatory and CD4+ T cell responses at sites of infection. [J Virol] Abstract

    KLF4 Modulates Expression of IL-6 in Dendritic Cells via Both Promoter Activation and Epigenetic Modification
    Researchers showed a novel role for the zinc finger transcription factor Kruppel like factor 4 (KLF4) in the modulation of the inflammatory immune response via its regulation of IL-6. They analyzed the role of KLF4 in the production of IL-6 by dendritic cells. [J Biol Chem] Abstract | Full Article

    Innate Immune-Directed NF-κB Signaling Requires Site-Specific NEMO Ubiquitination
    Scientists knock in a NF-κB essential modulator (NEMO) allele in which two major inflammatory agonist-induced ubiquitination sites cannot be ubiquitinated. They showed that mice with a nonubiquitinatable NEMO allele display embryonic lethality. Heterozygous females develop inflammatory skin lesions, decreased B cell numbers, and hypercellular spleens. [Cell Rep] Abstract | Graphical Abstract | Full Article

    Don’t forget to subscribe to our sister publications: Human Immunology News and Immunology of Infectious Disease News!

    Isolate Mouse Cells In As Little As 15 Minutes

     
    REVIEWS
    CTLA-4 and Autoimmunity: New Insights into the Dual Regulator of Tolerance
    Multiple single-nucleotide polymorphisms have been located to human Ctla-4 gene, and their association with autoimmune disease is still a matter of controversy. Despite the promising results of abatacept or CTLA-4-Ig in rheumatoid arthritis and murine lupus nephritis, more clinical randomized trials and standardization of outcomes are needed to prove its efficacy and safety in human lupus nephritis. [Autoimmun Rev] Abstract

    Invariant Natural Killer T Cells in Adipose Tissue: Novel Regulators of Immune-Mediated Metabolic Disease
    The authors summarize recent work on invariant natural killer T (iNKT) cells in immune regulation, with an emphasis on adipose tissue-resident iNKT cells, and identify the potential mechanisms by which adipocytes can mediate iNKT cell activity. [Cell Mol Life Sci] Abstract

    Visit our reviews page to see a complete list of reviews in the immune regulation field.

     
    INDUSTRY NEWS
    Immunomedics Constructs New Humanized Antibody for B-cell Mediated Cancer and Autoimmune Diseases
    Immunomedics, Inc. reported the issuance of U.S. Patent 8,486,395 with expiration on August 2, 2024. The new patent covers additional claims for the patent family, “Anti-CD19 Antibodies.” The allowed claims protect our new, proprietary humanized hA19 antibody and cover its use for the treatment of B-cell lymphoma, chronic lymphocytic leukemia or acute lymphocytic leukemia. [Immunomedics, Inc.] Press Release

    Researcher Finds Way to Convert Blood Cells into Autoimmune Disease Treatment
    Cells from one’s own blood could be converted into a treatment for autoimmune diseases, like rheumatoid arthritis and Crohn’s disease, based on the discovery of a Purdue University researcher. Chang Kim, a professor of comparative pathobiology, has created a way to direct the differentiation of T-cells, a white blood cell that is a key player in the body’s immune system. The method uses naïve T-cells, immature cells from which all T-cells develop, and induces them to become suppressive T-cells that block the development of painful inflammation associated with autoimmune diseases. [Purdue University] Press Release

    ARIAD Names Sarah J. Schlesinger, M.D. of Rockefeller University to Its Board of Directors
    ARIAD Pharmaceuticals, Inc. announced the appointment of Sarah J. Schlesinger, M.D., senior attending physician and associate professor of clinical investigation in the Laboratory of Cellular Physiology and Immunology at The Rockefeller University, to its Board of Directors. Dr. Schlesinger is a prominent clinical investigator and immunologist who has spent more than 20 years working in the field of cellular immunity, including as clinical director of the laboratory led by the late Ralph M. Steinman, M.D., 2011 Nobel Laureate in Physiology or Medicine. [ARIAD Pharmaceuticals, Inc.] Press Release

    NeoStem Advances Autoimmune Platform through UCSF Collaboration
    NeoStem, Inc. announced that the Company has executed agreements with the University of California, San Francisco (UCSF) and the laboratories of Jeffrey Bluestone, PhD, and Qizhi Tang, PhD, to collaborate on the development of human regulatory T cells for the treatment of type 1 diabetes, steroid resistant asthma, and organ transplant rejection. [NeoStem, Inc.] Press Release

    From our sponsor:
    View immunology lectures, protocols and other resources on the Human Immunology Portal.

     
    POLICY NEWS
    National Institutes of Health (United States)

    Food and Drug Administration (United States)

    Center for Biologics Evaluation and Research (United States)

    European Medicines Agency (European Union)

    Medicines and Healthcare Products Regulatory Agency (United Kingdom)

    Therapeutic Goods Administration (Australia)

     
    EVENTS
    NEW Keystone Symposia on Molecular and Cellular Biology: Tissue-Resident Memory T Cells
    January 12-16, 2014
    Snowbird, United States

    Visit our events page to see a complete list of events in the immune regulation community.

     
    JOB OPPORTUNITIES
    NEW Postdoctoral Fellowship – Immune Regulation and Regulatory T Cells in Inflammation (University of Oslo – Centre for Immune Regulation)

    Postdoctoral Position – Immunology (Mount Sinai School of Medicine)

    PhD Research Position – Immune Tolerance and Autoimmunity (Weizmann Institute of Science)

    Postdoctoral Fellowship – Immunology (Johns Hopkins University School of Medicine)

    PhD Position – MMP-9 Domain Structure Involvement in Immunomodulation (KU Leuven)

    PhD Research Position – Molecular and Cellular Mechanisms of Immune Tolerance and Autoimmunity (Weizmann Institute of Science)

    Postdoctoral Scientists – Immune Cell Biology (Medical Research Council – National Institute for Medical Research)

    Director of Cell Processing Facility (S L Collins Associates, Inc.)

    Junior or Senior Group Leader – Immunology/Infection/Inflammation (Center of Pathophysiology of Toulouse Purpan)

    Postdoctoral Position – Mechanistic Studies in Immune Responses (Medical University of Vienna)


    Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

     

    Have we missed an important article or publication in Immune Regulation News? Click here to submit!

    Comments or Suggestions? Email info@connexoncreative.com with your feedback.

    Learn more about Immune Regulation News: Archives | Events | Contact Us